Page last updated: 2024-12-06

coumalic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Coumalic acid is a heterocyclic compound with a pyran-2-one ring. It was first synthesized in 1883 by the German chemist Johannes Wislicenus. Coumalic acid can be synthesized through a variety of methods, including the condensation of ethyl acetoacetate with diethyl oxalate or the reaction of malonic acid with ethyl formate. Coumalic acid is a versatile building block for the synthesis of other heterocyclic compounds. It has been used to synthesize a variety of natural products, including the antibiotic coumermycin A1 and the anti-inflammatory agent coumarin. Coumalic acid is also a precursor to a number of synthetic drugs. It is an important compound in the study of organic chemistry and its applications in medicinal chemistry. Its unique structure and reactivity have made it a target for research in the areas of drug discovery and development.'

coumalic acid: RN given for parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68141
CHEMBL ID216734
CHEBI ID180952
SCHEMBL ID258740
MeSH IDM0149789

Synonyms (55)

Synonym
CHEBI:180952
6-oxo-pyran-3-carboxylic acid
F2170-0001
coumalic acid
2-pentenedioic acid, .delta.-lactone
500-05-0
2-oxopyran-5-carboxylic acid
cumalic acid
.alpha.-pyrone-5-carboxylic acid
2h-pyran-5-carboxylic acid, 2-oxo-
nsc22978
nsc-22978
6-oxopyran-3-carboxylic acid
inchi=1/c6h4o4/c7-5-2-1-4(3-10-5)6(8)9/h1-3h,(h,8,9
2-oxo-2h-pyran-5-carboxylic acid
2-oxo-1,2h-pyran-5-carboxylic acid
coumalic acid, 97%
STK329418
alpha-pyrone-5-carboxylic acid
CHEMBL216734
AKOS000119258
2-pyrone-5-carboxylic acid
ob1jpy343g ,
unii-ob1jpy343g
2-pentenedioic acid, 4-(hydroxymethylene)-, delta-lactone
nsc 22978
einecs 207-899-0
A827929
BBL009090
BP-12397
FT-0624076
coumalic acid [mi]
2-pentenedioic acid, 4-(hydroxymethylene)-, .delta.-lactone
2-oxo-1(2h)-pyran-5-carboxylic acid
glutaconic acid, 4-(hydroxymethylene)-, .delta.-lactone
SCHEMBL258740
AB00990923-03
AB00990923-01
coumalicacid
Q-103227
J-650096
2-oxo-2h-pyran-5-carboxylic acid #
.alpha.-pyrone-3-carboxylic acid
mfcd00006644
NCGC00336326-01
CS-0001427
DTXSID60870569
(e)-2-butenedioicaciddiethylester
AS-17705
Q19903002
EN300-19035
SB40457
SY020314
HY-32004
Z104472302
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyranoneAny of a class of cyclic chemical compounds that contain an unsaturated six-membered ring with one ring oxygen atom and an oxo substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID274670Inhibition of ADCS2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Aminodeoxychorismate synthase inhibitors from one-bead one-compound combinatorial libraries: "staged" inhibitor design.
AID498706Inhibition of beta lactamase CTX-M assessed as hydrolysis of beta lactam up to 5 mM by spectrometry analysis2009Nature chemical biology, May, Volume: 5, Issue:5
Molecular docking and ligand specificity in fragment-based inhibitor discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's2 (22.22)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.92 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]